Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Zoetis (NY:ZTS)

142.90 +0.78 (+0.55%)
Streaming Delayed Price Updated: 12:30 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Zoetis

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Zoetis Earnings Perspective: Return On Invested Capital
According to Benzinga Pro, during Q1, Zoetis (NYSE:ZTS) earned $594.00 million, a 43.83% increase from the preceding quarter. Zoetis also posted a total of $1.99 billion in sales, a 0.97% increase... 
Via Benzinga
Zoetis Declares Third Quarter 2022 Dividend
From Zoetis Inc.
Via Business Wire
7 Defensive Dividend Healthcare Stocks to Buy Now
As market conditions remain rocky, adding high-quality healthcare stocks to your portfolio may be a great way to play defense. 
Via InvestorPlace
Zoetis Delivers First-Quarter Beat, But Guidance Takes An Unexpected Hit
Zoetis posted a strong earnings number Thursday, but the guidance haircut was unexpected. 
Via Investor's Business Daily
Zoetis: Q1 Earnings Insights
Zoetis (NYSE:ZTS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Zoetis beat estimated earnings by 7.32%,... 
Via Benzinga
Zoetis: Q4 Earnings Insights
  Zoetis (NYSE:ZTS) reported its Q4 earnings results on Tuesday, February 15, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Zoetis Announces First Quarter 2022 Results
From Zoetis Inc.
Via Business Wire
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell • Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million. 
Via Benzinga
CNBC's Final Trades: Zoetis, VanEck Gold Miners ETF, Paramount Global And This Energy Stock
On CNBC’s “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors said Zoetis Inc (NYSE: ZTS) is “the largest provider of vaccines and medicines for pets and live 
Via Benzinga
Why Stephanie Link Is Watching Starbucks And This Stock Down Nearly 30% YTD
Hightower Advisors' Stephanie Link believes we are still in the midst of a bull market. Accordingly, she has identified a couple of stocks well off their highs that she would like to buy on any further... 
Via Benzinga
Zoetis Foundation Announces First Round of 2022 Grants to Advance Farmer and Veterinarian Education, Livelihoods and Wellness
From Zoetis Inc.
Via Business Wire
Blue-Chip Pharma Stock Among Best to Own This Quarter
With the second quarter currently underway, traders have the chance to revisit their portfolios and make any necessary adjustments. 
Via Talk Markets
Zoetis to Host Webcast and Conference Call on First Quarter 2022 Financial Results
From Zoetis Inc.
Via Business Wire
The New 'Return On Character' ETF Doesn't Include Musk Or Zuckerberg: Who Made The Cut?
A new active ETF launched this week with a unique spin on how it picks the companies to include in the fund. What Happened: ROC I... 
Via Benzinga
3 Beaten-Down Growth Stocks With More Than 50% Upside Potential
The key to picking growth stocks right now is to look for companies whose earnings momentum and growth can withstand any market conditions. 
Via InvestorPlace
Zoetis to Participate in the Bank of America Securities 2022 Animal Health Summit
From Zoetis Inc.
Via Business Wire
Zoetis's Return On Capital Employed Insights
Pulled from Benzinga Pro data, Zoetis (NYSE:ZTS) posted Q4 earnings of $413.00 million, an increase from Q3 of 25.18%. Sales dropped to $1.97 billion, a 1.16% decrease between quarters. 
Via Benzinga
4 Top Stock Trades for Wednesday: NVDA, SPCE, ABNB, ZTS
Nvidia, Virgin Galactic, Airbnb and Zoetis were our top stock trades for Wednesday. Here's how the charts are setting up right now. 
Via InvestorPlace
Zoetis Tops Quarterly Forecasts As Spot And Fluffy Contribute To Sales Growth
Companion animal sales continued their lead with livestock sales falling again. 
Via Investor's Business Daily
Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook
Zoetis Inc (NYSE: ZTS) has reported Q4 FY21 revenue of $2 b 
Via Benzinga
Zoetis Q4 Sales Cushioned By Higher Companion Animal Product Sales, Issues FY22 Outlook
Zoetis Inc. has reported Q4 FY21 revenue of $2 billion, an increase of 9% Y/Y, beating the consensus of $1.93 billion. 
Via Talk Markets
Zoetis Reports Fourth Quarter and Full Year 2021 Results
From Zoetis Inc.
Via Business Wire
Earnings Scheduled For February 15, 2022
Companies Reporting Before The Bell • FirstService (NASDAQ:FSV) is estimated to report quarterly earnings at $1.31 per share on revenue of $1.07 billion. 
Via Benzinga
Earnings Outlook For Zoetis
Zoetis (NYSE:ZTS) is set to give its latest quarterly earnings report on Tuesday, 2022-02-15. Here's what investors need to know before the announcement. Analysts estimate that Zoetis will report an... 
Via Benzinga
Zoetis Declares Second Quarter 2022 Dividend
From Zoetis Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
7 of the Top-Rated Pharmaceutical Stocks for Q1
As the market begins to shift from high-growth, tech-fueled start-ups, one good long-term growth option is quality pharmaceutical stocks. 
Via InvestorPlace
Zoetis's Ex-Dividend Date Is Tuesday, Here's What You Need To Know
Tuesday marks the last chance for investors to receive the next dividend payout from Zoetis. What's Happening (NYSE: 
Via Benzinga
FDA Approves Zoetis' Solensia To Control Osteoarthritis Pain In Cats
The FDA has approved Zoetis Inc's (NYSE: ZTS) Solensia (frunevetmab injection) to control the pain of osteoarthritis (OA) in cats, helping improve their... 
Via Benzinga
Zoetis Announces FDA Approval of Solensia™ (frunevetmab injection) to Control Osteoarthritis Pain in Cats
From Zoetis Inc.
Via Business Wire
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.